Nucleic acid molecules encoding nuclease-albumin fusion proteins
US12163165B2 · kind B2 · utility
0Cited by
74References
57Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2021 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Mar 30, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.